In addition to its tumor promoting role, prior studies have suggested Ror2's potential as a prognostic biomarker, with high Ror2 expression correlating with surgical stage and tumor metastasis in osteosarcoma [21], metastatic melanoma [19], [22], and poorer clinical outcome in colorectal cancer, GIST and leiomyosarcoma [11], [16]. This evidence concerns the gene ROR2 and gastrointestinal stromal tumor.